Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus

Phase 2

Completed

Conditions: Mixed Tumor, Mullerian

Interventions: Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2007-07-17

Last Posted Date: 2016-05-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00502203

Locations: 🇺🇸
Lyndon Baines Johnson Hospital, Houston, Texas, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Loma Linda Cancer Institute, Loma Linda, California, United States

and more 1 locations

Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: 5-Fluorouracil
Drug: Epirubicin
Drug: Cyclophosphamide
Drug: RAD001

First Posted Date: 2007-07-11

Last Posted Date: 2016-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 62

Registration Number: NCT00499603

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: paclitaxel
Other: placebo
Drug: sorafenib tosylate

First Posted Date: 2007-07-11

Last Posted Date: 2019-05-03

Lead Sponsor: Northwestern University

Target Recruit Count: 180

Registration Number: NCT00499525

Locations: 🇺🇸
Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States
🇺🇸
Northwest Alabama Cancer Center, PC - Muscle Shoals, Muscle Shoals, Alabama, United States
🇺🇸
Pacific Cancer Medical Center, Incorporated, Anaheim, California, United States

and more 39 locations

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: therapeutic autologous dendritic cells
Drug: aromatase inhibition therapy
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: paclitaxel
Drug: tamoxifen citrate
Genetic: gene expression analysis
Genetic: protein expression analysis
Genetic: reverse transcriptase-polymerase chain reaction
Other: immunoenzyme technique
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Procedure: adjuvant therapy
Procedure: biopsy
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Radiation: radiation therapy

First Posted Date: 2007-07-11

Last Posted Date: 2023-09-29

Lead Sponsor: University of Nebraska

Target Recruit Count: 17

Registration Number: NCT00499083

Locations: 🇺🇸
Eppley Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida, United States

Phase I Study in Patients With Solid Tumours

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: AZD0530
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2007-07-04

Last Posted Date: 2010-09-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 148

Registration Number: NCT00496028

Locations: 🇬🇧
Research Site, Sutton, United Kingdom

Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Carboplatin
Radiation: Proton Radiotherapy
Drug: Paclitaxel

First Posted Date: 2007-07-02

Last Posted Date: 2019-02-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 84

Registration Number: NCT00495170

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Head and Neck Squamous Cell Carcinoma
Metastatic Squamous Cell Carcinoma of the Larynx
Metastatic Squamous Cell Carcinoma of the Oral Cavity
Metastatic Squamous Cell Carcinoma of the Oropharynx
Recurrent Oropharyngeal Squamous Cell Carcinoma
Metastatic Squamous Cell Carcinoma of the Hypopharynx
Recurrent Head and Neck Squamous Cell Carcinoma
Recurrent Hypopharyngeal Squamous Cell Carcinoma
Recurrent Laryngeal Squamous Cell Carcinoma
Recurrent Oral Cavity Squamous Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: Sorafenib

First Posted Date: 2007-06-29

Last Posted Date: 2024-12-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 48

Registration Number: NCT00494182

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery

Phase 2

Terminated

Conditions: Esophageal Cancer

Interventions: Drug: cisplatin
Drug: gefitinib
Drug: paclitaxel
Procedure: adjuvant therapy
Radiation: radiation therapy

First Posted Date: 2007-06-27

Last Posted Date: 2018-12-06

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 19

Registration Number: NCT00493025

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis

Phase 1

Completed

Conditions: Peritoneal Cancer

Interventions: Drug: Bevacizumab
Drug: Oxaliplatin
Drug: Paclitaxel

First Posted Date: 2007-06-26

Last Posted Date: 2013-01-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00491855

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer

Phase 2

Completed

Conditions: Epithelial Ovarian Cancer

First Posted Date: 2007-06-25

Last Posted Date: 2007-06-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 7

Registration Number: NCT00490711

Locations: 🇸🇰
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bratislava, Slovakia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy